My Medication Side Effects Are Too Popular

Fu Xinming also looked at the list of prescriptions listed above, many of which were marked with obvious toxic and side effects.

"Son, do these work?

Fu Liang leaned on the chair: "Most of them are definitely unusable, and the toxicology test failed, and I'm afraid it will be difficult for me to find other application directions.

"But isn't there some toxicology tests that are okay, but the efficacy is much lower than that of Yuqi, these are what I need.

Fu Xinming looked at Fu Liang seriously: "Can you really find a new treatment direction from these and successfully develop it?

"Dad, haven't you seen my previous achievements?

Fu Liang asked back:

Fu Xinming shook his head: "It's not the same. Before, they were all purchased from domestic pharmaceutical companies. The R&D level of many pharmaceutical companies is [-] years behind foreign countries.

The new application direction is not surprising

"Johnson & Johnson is the world's leading pharmaceutical company, and their R&D capabilities are among the world's top."

"Forget it, what if it's a waste? Anyway, I won't give in on other conditions. I see which shareholder dares to have an objection!

Fu Liang looked at his father: "Dad, no one knows better than me how to find Ning from discarded prescriptions!"

PS: Ask for flowers, ask for evaluation, ask for collection!!!

Chapter [-]: The contract is signed, the net worth is tens of billions!

In the large conference room of Xinming Pharmaceutical Company, a high platform was arranged again.

On the background board of the high platform is the signing ceremony of the establishment of a joint venture between Xinming Pharmaceutical and Johnson & Johnson.

Fu Xinming signed a contract with the CEO of Johnson & Johnson. The two sides exchanged signatures and took pictures.

On the high platform, Zhang Hengyuan, the main leader of the province, was also present. Even Song He of the Provincial Food and Beverage Supervision Bureau could only stand by Edward.

For such a big project, just Song He's attendance doesn't show the level of attention.

Zhang Hengyuan held Fu Xinming's hand:

"Mr. Fu, you Xinming Pharmaceutical gave me a big surprise, four billion dollars just got it.

Fu Xinming shook his head: "Leader, you don't have four billion, and you have to pay taxes.

Zhang Hengyuan looked at Fu Xinming in amazement: "Don't you know? Song He helped you submit a national-level application for a special list of major new drug creations two days ago.

Please, it is estimated that it has already arrived at the General Administration. It is not a big problem.

"As long as this is passed, then you Xinming Pharmaceutical can get tax-free preferential policies this year. Mr. Fu, the province is very supportive of you.

The company's headquarters should not be relocated.

When the new drug is put into production next year, it will continuously obtain tax revenue and promote local employment. This is what Zhang Hengyuan values ​​more.

Representatives of many pharmaceutical companies looked at the CEO of Johnson & Johnson with envy.

The CEO of Johnson & Johnson looked at Fu Xinming and Fu Liang. It is estimated that many people do not know that the Fu family is the biggest beneficiary.

The shareholding structure of Xinming Pharmaceutical is not complicated, but the rights and interests of this new drug do not completely belong to Xinming Pharmaceutical. Fortunately, other rights and interests still belong to the company.

This time, the painkiller project of Sutongstop will be separated out and injected into a joint venture subsidiary.

The subsidiary's equity is divided into three shares, Xinming Pharmaceutical holds [-]%, Johnson & Johnson holds [-]%, and Fu Liang's mother holds shares

[-]%, Fu Liang personally holds [-]%

All this is thanks to the supplementary agreement that Dad asked the shareholders to sign. Fu Liang will get [-]% of the new drug developed by him.

The $[-] billion paid by Johnson & Johnson will also be divided into three parts, which will belong to Xinming Pharmaceutical, Fu Liang and Fu Liang's mother.

Only [-] billion US dollars was allocated to Xinming Pharmaceutical, and the bulk of it belonged to Fu Xinming.

The remaining [-] billion US dollars belonged to Fu Liang and his family. Converted into RM coins, it exceeded [-] billion!

$[-] billion to be paid within a week and another $[-] billion to be paid after Phase [-]

The money will be paid in two installments,

If the third clinical phase proves that the drug fails, all the money will be returned

Fu Liang agreed to Johnson & Johnson's request at the time, because he could guarantee that the drug would never fail!

Celebrated with Johnson & Johnson and the company's shareholders. In the evening, Fu Liang returned to his parents' home.

The two of them didn't drink much when they opened, and when they got home, the two of them sat down at the dining table again and opened a few cans of beer.

") son, we Xinming Pharma have finally really embarked on the fast lane.

Fu Xinming took a sip of beer, his face a little rosy,

If domestic drugs want to enter the European and American markets, the procedures are very cumbersome, and they are easily obstructed by the FDA in the United States.

These large pharmaceutical companies have a certain influence on the FDA.

And after the US FDA certification, re-certification in Europe will not be too hindered.

Not just to get a large sum of money, so that Xinming Pharmaceutical can quickly develop its own products and other drugs

So cooperate with Johnson & Johnson,

And this is still a knock on the door. As long as the door is opened, it will be easier for new drugs to enter the US and European markets in the future.

After that, there is no need to cooperate with other pharmaceutical companies for other medicines of Xinming Pharmaceutical. They can develop their own and have enough strength to develop them.

This time, Johnson & Johnson will act as an agent for the sales of Sudentine in overseas markets, and will rely on their experience to help Xinming Pharma set the price of Sudagon.

Guaranteed highest profit

Borrowing the sales channels of Johnson & Johnson, the name of Xinming Pharmaceutical has been quickly established in the world.

When new drugs are introduced later, it will be easier

, Johnson & Johnson will also solve it, after all, there are also their interests here.

Ganta's great medicine Zuoruli wants to stretch a stumbling block

Of course, Johnson & Johnson is not at a loss. First, it can share one-third of the project revenue. Second, one year before the patent protection expires, the drug patent will be released.

Licensed to Johnson & Johnson, the license fee is calculated separately.

In this way, Johnson & Johnson can become the second largest painkiller manufacturer after Shinming, and continue to maintain their leading position in the painkiller market.

"Dad, the business adjustment of our Xinming Pharmaceutical is about to end, right?

After Fu Liang developed hair and hair medicine and hair removal cream,

, the business of Xinming Pharmaceutical has been adjusting

Purchasing new production lines, technological innovation,

, stop some unprofitable drugs,

Up to now, [-]% of the original drug production has been stopped, and it can be completely stopped until some contracts are completed.

Anyway, those broad-spectrum generic drugs are not profitable, and most pharmaceutical companies can produce them, and the competition is too great.

This kind of medicine can make money, either by entering the medical insurance bureau's procurement list, or by changing its name.

, then package it up and sell it at a high price

"It's almost two months away, and the approval for the hair growth medicine should almost come down.

Johnson & Johnson actually wanted to license the patent for the hair growth drug, but Fu Xinming did not agree.

They are not in a hurry to sell this hair growth drug, they will first gain popularity in the domestic market,

, and then the FDA application in the United States is estimated to have passed.

At that time, Xinming Pharmaceutical's Supain should also be launched in Europe and the United States, which happened to develop together.

The big deal, when the time comes, let Johnson become a sales agent, and the management will be more worry-free.

Anyway, in the future, Xinming Pharmaceutical will only sell the special new drugs developed by his son. In the future, Xinming Pharmaceutical will be built into a new special medicine R&D and production enterprise.

In this way, the company has stronger anti-risk ability, higher profit margins and higher visibility.

, that is, there is no cure for those life-threatening diseases, which

But the only downside is that none of the products currently under development treat serious diseases.

It is an important factor to measure the strength of a pharmaceutical company

However, Fu Xinming is not in a hurry. He feels that with his son's talent, sooner or later, he will be able to develop that kind of effective new medicine for the treatment of serious diseases.

Only one or two new ones are launched every year

"Son, is there any eye for new drug research and development? Don't worry, even a pharmaceutical company like Johnson & Johnson,

Medicine, the rest is just to upgrade the formula and improve the craft, your speed is already very fast.

Fu Liang smiled slightly: "Dad, about the research and development of new drugs, just leave it to me.

"Wait, I'm going to surprise the global pharmaceutical companies again soon, and let them know that we didn't just get away with a new drug, but

It has new drug research and development capabilities that they could not have imagined!

PS: Ask for flowers, ask for evaluation, ask for collection!!! College candidates who have finished the exam hurry up, after all, after the grades are down, they may not be able to wave again!

Chapter [-]: This side effect is awesome!

After two days of relaxation, Fu Liang returned to the Drug Research and Development Experimental Center.

In the past few days, Chinese and foreign media have been interviewing Xinming Pharmaceutical, and many of them were recruited by Johnson & Johnson, which was regarded as a kind of advance publicity.

Fu Liang also avoided the media. It was annoying to be interviewed every day, but the lab was clean.

Nowadays, the offices of the Drug Research and Development Experimental Center, especially Fu Liang's office, are full of information on various new drug projects.